FluoGuide’s Q3 2025 report, published last week, highlights the company’s operational progress as the company advances its lead candidate FG001 towards future commercialisation. The quarter also reflects strengthened financial resources, increasing regulatory clarity and an expanding network of industry partnerships that support the company’s long-term strategy. BioStock contacted CEO Morten Albrechtsen for additional comments on the quarter’s developments.
Read the full article at biostock.se:
https://biostock.se/en/2025/12/fluoguide-understryker-operativa-framsteg-under-q3/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/